The CEO of BioNTech has stated that the company and its partner Pfizer have been successful in further enhancing their highly sought-after production capacity after the Kovid-19 vaccine, with a supply of nearly three billion doses in 2021.
Speaking at a webcast event organized by the Financial Times on Tuesday, UGur Sahin, CEO and co-founder of Biotech, said that the company has been lucky so far and was “Not experiencing too many technical problems and scheduling our delivery.”
Sahin said the production manufacturing capacity was extended to allow the manufacture of three billion biotech-Pfizer shots in 2021 from the previous target of 2.5 billion.
Our teams did a huge job to further increase the manufacturing scale with numbers reaching three billion doses.
In March, the Mainz-based biotech company said that its partners at Pfizer increased their production capacity, allowing 2.5 billion to be built this year, of which 1.4 billion had already been sold.
Also on rt.com
In 2022, CEO targets production of 3bn Kovid vaccines in 2022, warning after future inspection
Last week, Modern President Stephen Hoge said his company would produce three billion shots of its own jab in 2022, depending on how many shots are low-dose totals for boosters and vaccination for children. .
Morden CEO Stephen Bansell warned that in 2022 the world could monitor Kovid-19 vaccines and that it could be challenging for developers like myself.
China claims it will have the capacity to produce five billion jabs by the end of the year, while Britain, a relatively small country by population, produces at least three vaccines, AstraZeneca, Novavax and Walneva, before the end of 2021. Will do. Neither Pfizer or Modern Jab is likely to be manufactured in the country.
If you liked this story then share it with a friend!